<DOC>
	<DOCNO>NCT02761122</DOCNO>
	<brief_summary>Lichen planus chronic cutaneous mucosal disease characterize infiltration cluster differentiation ( CD ) CD8 T lymphocytes , localize basal membrane associate apoptosis basal keratinocytes , suggest reactivity T lymphocytes toward keratinocyte antigen ( ) , far unidentified . In recent study , research team Institut Pasteur demonstrate peculiar clinical form lichen planus ( erosive lichen planus ) , immunogenic target CD8 T lymphocyte could immunodominant peptide Human Papilloma Virus ( HPV ) 16 . In line recent work show first time link HPV-16 autoimmune disease , erosive lichen planus , aim te study test hypothesis HPV could also involve pathogenesis clinical form lichen , non erosive lichen planus lichen sclerosus .</brief_summary>
	<brief_title>Implication Human Papillomavirus ( HPV ) Lichen Physiopathology Human ( HPVLichen )</brief_title>
	<detailed_description>Lichen planus chronic cutaneous mucosal disease characterize infiltration cluster differentiation ( CD ) CD8 T lymphocytes , localize basal membrane associate apoptosis basal keratinocytes , suggest reactivity T lymphocytes toward keratinocyte antigen ( ) , far unidentified . In recent study , research team Institut Pasteur demonstrate peculiar clinical form lichen planus ( erosive lichen planus ) , immunogenic target CD8 T lymphocyte could immunodominant peptide Human Papilloma Virus ( HPV ) 16 . In line recent work show first time link HPV-16 autoimmune disease , erosive lichen planus , aim te study test hypothesis HPV could also involve pathogenesis clinical form lichen , non erosive lichen planus lichen sclerosus . Regarding erosive lichen planus , aim test cytotoxic function previously identify CD8 T lymphocytes specific HPV16 E711-20 .</detailed_description>
	<mesh_term>Lichen Planus</mesh_term>
	<criteria>At least 18 yearold Clinically histologically confirm lichen : Nonerosive lichen planus , Erosive lichen planus , Sclerosus lichen At diagnosis desease treatment , flare disease , without intake topical application immunosuppressant Affiliated beneficiary social security system Informed write consent Under 18 yearold , Legal protection measure , Inability consent Pregnant breastfeeding woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>